中化合成 CENRA+ API Solutions

2026 H1 Investor Conference

2026/09/16



中化合成
CENRA•API Solutions

Safe Harbor Notice

- **CCSB's presentation contains forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from those contained in the forward-looking statements.**

- **The forward-looking statements in this release reflect the current belief of CCSB as of the date of this release. We undertake no obligation to update these forward-looking statements for new information, future events or otherwise.**

中化合成
CENRA• API Solutions

Company

- **Stock Code:1762**
- **Employee: 247 (As of 2026/6/30)**
- **2026 H1 Revenue 0.6 billion, with EPS NT$2.39 , Net Sales up 24% YoY.**
- **We focus on two core businesses: Specialty API (high-tech API) and CDMO (contract development and manufacturing services).**

- **Brief History**
- **Founded in 1964**
  - ✓ The first registered and one of the largest bulk pharmaceutical chemical manufacturers in Taiwan
  - ✓ First FDA-approved plant (1984) in Taiwan
- **Turning Points**
  - ✓ Formed the New Management Team in 1997, and established 4 cGMP Production Lines for Synthetic Products and 2 cGMP Production Lines for Biotechnology Products
  - ✓ Established US Sales Office: Pharmaports in 2000
  - ✓ Initial public offering on December 20, 2010

中化合成
CENRA•API Solutions

Key Strengths

- An API factory with bio-fermentation and chemical synthesis technology and equipment.
- Ensure compliance with and successfully pass inspections by the US FDA and European PIC/S regulations.
- With certified API master file DMFs for a variety of products, our export products are competitive.
- From small batch research and development to mass production of APIs, offering comprehensive one-stop services.
- Collaborate with strategic partner and establish technical platforms to expand and promote CDMO offerings

中化合成
CENRA•API Solutions

US DMF List

17399 •RAPAMYCIN	18494 •MYCOPHENOLATE MOFETIL USP	18985 •TACROLIMUS	23213 •TACROLIMUS SD20	24372 •MYCOPHENOLATE MOFETIL HYDROCHLORIDE ANHYDROUS	26271 •ETHYL ICOSAPENTATE
26819 •EVEROLIMUS PRE-MIX USP	27216 •EVEROLIMUS USP	27585 •CASPOFUNGIN ACETATE	31189 •RAPAMYCIN (SIROLIMUS)	33333 •MYCOPHENOLATE MOFETIL USP (PROCESS B)	35848 •MYCOPHENOLATE SODIUM USP
36030 •BARICITINIB	36174 •RIBOCICLIB SUCCINATE	36640 •MIDOSTAURIN	37532 •TOFACITINIB CITRATE	37586 •PALBOCICLIB	37597 •OZANIMOD HYDROCHLORIDE
38111 •EVEROLIMUS B02 USP	38310 •TACROLIMUS (PROCESS B)	38511 •DIFELIKEFALIN ACETATE	40868 • ELTROMBOPAG OLAMINE	41490 • SETMELANOTIDE ACETATE	41491 • BRIVARACETAM
41492 • SELUMETINIB SULFATE	41493 • PLECANATIDE	41494 • TRILACICLIB DIHYDROCHLORIDE			

中化合成
CENRA•API Solutions

Key Products

- Active Pharmaceutical Ingredients (API) for branded drugs and generic drugs
  - Everolimus: It is used for an anticancer drug, cardiovascular stent coating and immunosuppressive applications.
  - Caspofungin Acetate: An echinocandin antifungal drug.
  - Rapamycin: An immunosuppressive agent also used in cancer therapy and as a coating for cardiovascular drug-eluting stents (DES).
  - Tacrolimus: An immunosuppressive agent, also used topically to treat autoimmune skin diseases such as atopic dermatitis.
  - Selumetinib Sulfate: A MEK inhibitor indicated for the treatment of neurofibromatosis type 1 (NF1).

中化合成
CENRA•API Solutions

Consolidated Comprehensive Income Statement

Amount: NT$ Thousand

Item \ Year	2026 H1	
	Amount	%
Net Sales	**666,405**	100
Gross Profit	266,282	**40**
Operating Profit	114,873	**17**
Profit before Tax	150,682	23
Net Profit	132,128	20
Basic EPS(NT$)	**2.39**	


中化合成
CENRA•API Solutions

2026 H1 Sales Distribution By Region

Region/ Product	%	EPAE	EVE	FK506	SEL	RAPA	CAS
US	54	●	●	●	●	●	
Asia	22		●	●	●	●	●
Europe	21		●			●	●
Taiwan	3		●	●			

中化合成
CENRA•API Solutions

Share of Revenue by Key Products



中化合成
CENRA•API Solutions

Latest News


Regulatory

- Completed US DMF review for Tacrolimus process.
- Successfully passed customers' on-site inspections from the US and Taiwan.

ESG

- Continue providing care for the elderly in the community this year , while continuing to implement ESG social care initiatives.

Future Outlook (1/2)



- Upon completion of SEL process validation, efforts will focus on entering the neurofibromatosis type 1 treatment, thereby broadening the product portfolio.
- The benefits of SET's expanded indication are expected to gradually materialize, driving increased customer interest and order demand. The Company will continue to deepen its market presence and capitalize on future growth opportunities.
- Short-term increase of revenue from CDMO/CMO. Develop drug substances in advance and engage in international new drug R&D collaborations.
- Continue to increase market penetration of FK506 and CAS.
- Registration approvals and regulatory change operations are conducted in multiple countries, with the goal of continuously expanding into new markets.

中化合成
CENRA•API Solutions

Future Outlook(2/2)


P4 & P3 Products (expected launch in 5-10 years)

- CKD-Associated Pruritus
  Difelikefalin Acetate
- Multiple Sclerosis
  Ozanimod HCl
- Genetic Obesity
  Setmelanotide Acetate
- SCLC Myelopreservation Therapy
  Trilaciclib 2HCl
- Antifungal
  Rezafungin Acetate

P3 Products (expected launch in 3-5 years)

- Neurofibromatosis Type 1
  Selumetinib Sulfate
- Hematology
  Eltrombopag Olamine
- Breast Cancer
  Palbociclib, Ribociclib Succinate
- Irritatble Bowel Syndrome, Hyperphosphatemia in CKD
  Tenapanor HCl


◆ Development Milestones



中化合成
CENRA•API Solutions

List of Abbreviations

Abbreviation	Full names	Treatments/Indications
CAS	Caspofungin Acetate	Antifungal
EPAE	Ethyl Icosapentate	Hypertriglyceridemia, Cardiovascular Risk Reduction
EVE	Everolimus	Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma, Organ Transplant, Rejection Prophylaxis
FK506	Tacrolimus	Organ Transplant, Rejection Prophylaxis
RAPA	Rapamycin (Sirolimus)	Immunosuppressant, Organ Transplant, Rejection Prophylaxis
SEL	Selumetinib Sulfate	Neurofibromatosis Type 1
SET	Setmelanotide Acetate	Genetic Obesity


Thank You
http://www.ccsb.com.tw
Stock Code ：1762
中化合成
CENRA+API Solutions
Embrace Life, Beyond Health